Moreover, since we observe that tumor-derived EVs can inhibit NK cell activity through MICA/B and TRAIL, deletion of CHMP2A limits the secretion of EVs by the tumor cells leading to enhanced NK cell-mediated cytotoxicity. The gene discussed is CHMP2A; the disease is neoplasm.